{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T19:21:19Z","timestamp":1772652079674,"version":"3.50.1"},"reference-count":182,"publisher":"Institute of Biochemistry","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BIOMED KHIM"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:p>The VPS35 is an essential protein that plays multifunctional roles in various biological processes. It is a core component of the retromer complex, involved in protein recycling from endosomes to the trans-Golgi network (TGN) and the plasma membrane. Besides its role as the retromer complex component, VPS35 interacts with many proteins and regulates mitochondrial homeostasis, mitochondrial dynamics (fusion and fission), and other important processes in various cell compartments. In the context of Parkinson\u2019s disease (PD) convincing evidence exists that VPS35 mutations, particularly [D620N], have a significant impact on normal retromer functioning, mitochondrial dysfunction, and impairment of neuronal health and survival. In this review we briefly consider structure and functions of the retromer complex, the role of VPS35 in mitochondria, and finally analyze physical and functional interactions of this protein with PD-important proteins associated with mitochondria.<\/jats:p>","DOI":"10.18097\/pbmcr1648","type":"journal-article","created":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T17:51:32Z","timestamp":1772646692000},"page":"5-20","source":"Crossref","is-referenced-by-count":0,"title":["The VPS35 protein and the role of its impairments in mitochondrial dysfunction in Parkinson\u2019s disease"],"prefix":"10.18097","volume":"72","author":[{"given":"O.A.","family":"Buneeva","sequence":"first","affiliation":[{"name":"Institute of Biomedical Chemistry, Moscow, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.E.","family":"Medvedev","sequence":"additional","affiliation":[{"name":"Institute of Biomedical Chemistry, Moscow, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7443","published-online":{"date-parts":[[2026]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Costa H.N., Esteves A.R., Empadinhas N., Cardoso S.M. (2022) Parkinson\u2019s disease: a multisystem disorder. Neurosci. Bull., 39(1), 113.","DOI":"10.1007\/s12264-022-00934-6"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Ben-Shlomo Y., Darweesh S., Llibre-Guerra J., Marras C., San Luciano M., Tanner C. (2024) The epidemiology of Parkinson\u2019s disease. Lancet, 403(10423), 283\u2013292.","DOI":"10.1016\/S0140-6736(23)01419-8"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"GBD 2016 Neurology Collaborators (2019) Global, regional, and national burden of neurological disorders, 1990\u20132016: a systematic analysis for the Global Burden of Disease study 2016. Lancet Neurol., 18(5), 459\u2013480.","DOI":"10.1016\/S1474-4422(18)30499-X"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Su D., Cui Y., He C., Yin P., Bai R., Zhu J., Lam J.S.T., Zhang J., Yan R., Zheng X., Wu J., Zhao D., Wang A., Zhou M., Feng T. (2025) Projections for prevalence of Parkinson\u2019s disease and its driving factors in 195 countries and territories to 2050: modelling study of Global Burden of Disease study 2021. BMJ, 388, e080952.","DOI":"10.1136\/bmj-2024-080952"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Armstrong M.J., Okun M.S. (2020) Diagnosis and treatment of Parkinson disease: a review. JAMA, 323(6), 548\u2013560.","DOI":"10.1001\/jama.2019.22360"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Baggett D., Olson A., Parmar M.S. (2024) Novel approaches targeting \u03b1-synuclein for Parkinson\u2019s disease: current progress and future directions for the disease-modifying therapies. Brain Disord., 16, 100163.","DOI":"10.1016\/j.dscb.2024.100163"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Oliveira L.M.A., Gasser T., Edwards R., Zweckstetter M., Melki R., Stefanis L., Lashuel H.A., Sulzer D., Vekrellis K., Halliday G.M., Tomlinson J.J., Schlossmacher M., Jensen P.H., Schulze-Hentrich J., Riess O., Hirst W.D., El-Agnaf O., Mollenhauer B., Lansbury P., Outeiro T.F. (2021) Alpha-synuclein research: defining strategic moves in the battle against Parkinson\u2019s disease. NPJ Parkinsons Dis., 7(1), 65.","DOI":"10.1038\/s41531-021-00203-9"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Morris H.R., Spillantini M.G., Sue C.M., Williams-Gray C.H. (2024) The pathogenesis of Parkinson\u2019s disease. Lancet, 403(10423), 293\u2013304.","DOI":"10.1016\/S0140-6736(23)01478-2"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Sulzer D., Edwards R.H. (2019) The physiological role of \u03b1-synuclein and its relationship to Parkinson\u2019s disease. J. Neurochem., 150(5), 475\u2013486.","DOI":"10.1111\/jnc.14810"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Kouli A., Torsney K.M., Kuan W.-L. (2018) Parkinson\u2019s disease: etiology, neuropathology, and pathogenesis. In: Parkinson\u2019s Disease: Pathogenesis and Clinical Aspects (Stoker T.B., Greenland J.C., eds.) Codon Publications, Brisbane (AU), pp. 3\u201326.","DOI":"10.15586\/codonpublications.parkinsonsdisease.2018.ch1"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Adler C.H., Beach T.G. (2016) Neuropathological basis of nonmotor manifestations of Parkinson\u2019s disease. Mov. Disord., 31(8), 1114\u20131119.","DOI":"10.1002\/mds.26605"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Marras C., Chaudhuri K.R. (2016) Nonmotor features of Parkinson\u2019s disease subtypes. Mov. Disord., 31(8), 1095\u20131102.","DOI":"10.1002\/mds.26510"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Langston J.W., Irwin I., Langston E.B., Forno L.S. (1984) 1-Methyl-4-phenylpyridinium ion (MPP+): identification of a metabolite of MPTP, a toxin selective to the substantia nigra. Neurosci. Lett., 48(1), 87\u201392.","DOI":"10.1016\/0304-3940(84)90293-3"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Buneeva O.A., Medvedev A.E. (2011) Mitochondrial dysfunction in Parkinson\u2019s disease. Biomeditsinskaya Khimiya, 57(3), 246\u2013281.","DOI":"10.18097\/PBMC20115703246"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Bose A., Beal M.F. (2016) Mitochondrial dysfunction in Parkinson\u2019s disease. J. Neurochem., 139(Suppl 1), 216\u2013231.","DOI":"10.1111\/jnc.13731"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Buneeva O.A., Medvedeva M.V., Kopylov A.T., Medvedev A.E. (2019) Ubiquitin subproteome of brain mitochondria and its changes induced by experimental parkinsonism and action of neuroprotectors. Biochemistry (Moscow), 84(11), 1359\u20131374.","DOI":"10.1134\/S0320972519110113"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Buneeva O.A., Medvedev A.E. (2006) Ubiquitin-protein ligase parkin and its role in the development of Parkinson\u2019s disease. Biochemistry (Moscow), 71(8), 851\u2013860.","DOI":"10.1134\/S0006297906080050"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Zhao Y., Lin M., Zhai F., Chen J., Jin X. (2024) Exploring the role of ubiquitin-proteasome system in the pathogenesis of Parkinson\u2019s disease. Pharmaceuticals, 17(6), 782.","DOI":"10.3390\/ph17060782"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Buneeva O., Medvedev A. (2022) Atypical ubiquitination and Parkinson\u2019s disease. Int. J. Mol. Sci., 23(7), 3705.","DOI":"10.3390\/ijms23073705"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Polymeropoulos M.H., Lavedan C., Leroy E., Ide S.E., Dehejia A., Dutra A., Pike B., Root H., Rubenstein J., Boyer R., Stenroos E.S., Chandrasekharappa S., Athanassiadou A., Papapetropoulos T., Johnson W.G., Lazzarini A.M., Duvoisin R.C., di Iorio G., Golbe L.I., Nussbaum R.L. (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson\u2019s disease. Science, 276(5321), 2045\u20132047.","DOI":"10.1126\/science.276.5321.2045"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Singleton A.B., Farrer M.J., Bonifati V. (2013) The genetics of Parkinson\u2019s disease: progress and therapeutic implications. Mov. Disord., 28(1), 14\u201323.","DOI":"10.1002\/mds.25249"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Lunati A., Lesage S., Brice A. (2018) The genetic landscape of Parkinson\u2019s disease. Rev. Neurol. (Paris), 174(9), 628\u2013643.","DOI":"10.1016\/j.neurol.2018.08.004"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Domingo A., Klein C. (2018) Genetics of Parkinson disease. Handb. Clin. Neurol., 147, 211\u2013227.","DOI":"10.1016\/B978-0-444-63233-3.00014-2"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Kim C.Y., Alcalay R.N. (2017) Genetic forms of Parkinson\u2019s disease. Semin. Neurol., 37(2), 135\u2013146.","DOI":"10.1055\/s-0037-1601567"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Cherian A., Divya K.P., Vijayaraghavan A. (2023) Parkinson\u2019s disease \u2014 genetic cause. Curr. Opin. Neurol., 36(4), 292\u2013301.","DOI":"10.1097\/WCO.0000000000001167"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Ye H., Robak L.A., Yu M., Cykowski M., Shulman J.M. (2023) Genetics and pathogenesis of Parkinson\u2019s syndrome. Annu. Rev. Pathol., 18, 95\u2013121.","DOI":"10.1146\/annurev-pathmechdis-031521-034145"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Nussbaum R.L. (2017) The identification of alpha-synuclein as the first Parkinson disease gene. J. Parkinsons Dis., 7(s1), S43\u2013S49.","DOI":"10.3233\/JPD-179003"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Vilari\u00f1o-G\u00fcell C., Wider C., Ross O.A., Dachsel J.C., Kachergus J.M., Lincoln S.J., Soto-Ortolaza A.I., Cobb S.A., Wilhoite G.J., Bacon J.A., Behrouz B., Melrose H.L., Hentati E., Puschmann A., Evans D.M., Conibear E., Wasserman W.W., Aasly J.O., Burkhard P.R., Djaldetti R., Ghika J., Hentati F., Krygowska-Wajs A., Lynch T., Melamed E., Rajput A., Rajput A.H., Solida A., Wu R.-M., Uitti R.J., Wszolek Z.K., Vingerhoets F., Farrer M.J. (2011) VPS35 mutations in Parkinson disease. Am. J. Hum. Genet., 89, 162\u2013167.","DOI":"10.1016\/j.ajhg.2011.06.001"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"Zimprich A., Benet-Pag\u00e8s A., Struhal W., Graf E., Eck S.H., Offman M.N., Haubenberger D., Spielberger S., Schulte E.C., Lichtner P., Rossle S.C., Klopp N., Wolf E., Seppi K., Pirker W., Presslauer S., Mollenhauer B., Katzenschlager R., Foki T., Hotzy C., Reinthaler E., Harutyunyan A., Kralovics R., Peters A., Zimprich F., Br\u00fccke T., Poewe W., Auff E., Trenkwalder C., Rost B., Ransmayr G., Winkelmann J., Meitinger T., Strom T.M. (2011) A mutation in VPS35, encoding a subunit of the retromer complex, causes late-onset Parkinson disease. Am. J. Hum. Genet., 89, 168\u2013175.","DOI":"10.1016\/j.ajhg.2011.06.008"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"Rahman A.A., Morrison B.E. (2019) Contributions of VPS35 mutations to Parkinson\u2019s disease. Neuroscience, 401, 1\u201310.","DOI":"10.1016\/j.neuroscience.2019.01.006"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"Sassone J., Reale C., Dati G., Regoni M., Pellecchia M.T., Garavaglia B. (2021) The role of VPS35 in the pathobiology of Parkinson\u2019s disease. Cell. Mol. Neurobiol., 41(2), 199\u2013227.","DOI":"10.1007\/s10571-020-00849-8"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"Sheerin U.-M., Charlesworth G., Bras J., Guerreiro R., Bhatia K., Foltynie T., Limousin P., Silveira-Moriyama L., Lees A., Wood N. (2012) Screening for VPS35 mutations in Parkinson\u2019s disease. Neurobiol. Aging, 33(4), 838.e1\u20135.","DOI":"10.1016\/j.neurobiolaging.2011.10.032"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"Wider C., Skipper L., Solida A., Brown L., Farrer M., Dickson D., Wszolek Z.K., Vingerhoets F.J.G. (2008) Autosomal dominant dopa-responsive parkinsonism in a multigenerational Swiss family. Parkinsonism Relat. Disord., 14(6), 465\u2013470.","DOI":"10.1016\/j.parkreldis.2007.11.013"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"Chen Y.-F., Chang Y.-Y., Lan M.-Y., Chen P.-L., Lin C.-H. (2017) Identification of VPS35 p.D620N mutation-related Parkinson\u2019s disease in a Taiwanese family with successful bilateral subthalamic nucleus deep brain stimulation: a case report and literature review. BMC Neurol., 17(1), 191.","DOI":"10.1186\/s12883-017-0972-5"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"Kumar K.R., Weissbach A., Heldmann M., Kasten M., Tunc S., Sue C.M., Svetel M., Kosti\u0107 V.S., Segura-Aguilar J., Ramirez A., Simon D.K., Vieregge P., M\u00fcnte T.F., Hagenah J., Klein C., Lohmann K. (2012) Frequency of the D620N mutation in VPS35 in Parkinson disease. Arch. Neurol., 69(10), 1360\u20131364.","DOI":"10.1001\/archneurol.2011.3367"},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"Ando M., Funayama M., Li Y., Kashihara K., Murakami Y., Ishizu N., Toyoda C., Noguchi K., Hashimoto T., Nakano N., Sasaki R., Kokubo Y., Kuzuhara S., Ogaki K., Yamashita C., Yoshino H., Hatano T., Tomiyama H., Hattori N. (2012) VPS35 mutation in Japanese patients with typical Parkinson\u2019s disease. Mov. Disord., 27(11), 1413\u20131417.","DOI":"10.1002\/mds.25145"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"Sharma M., Ioannidis J.P.A., Aasly J.O., Annesi G., Brice A., Bertram L., Bozi M., Barcikowska M., Crosiers D., Clarke C.E., Facheris M.F., Farrer M., Garraux G., Gispert S., Auburger G., Vilari\u00f1o-G\u00fcell C., Hadjigeorgiou G.M., Hicks A.A., Hattori N., Jeon B.S., Jamrozik Z., Krygowska-Wajs A., Lesage S., Lill C.M., Lin J.J., Lynch T., Lichtner P., Lang A.E., Libioulle C., Murata M., Mok V., Jasinska-Myga B., Mellick G.D., Morrison K.E., Meitnger T., Zimprich A., Opala G., Pramstaller P.P., Pichler I., Park S.S., Quattrone A., Rogaeva E., Ross O.A., Stefanis L., Stockton J.D., Satake W., Silburn P.A., Strom T.M., Theuns J., Tan E.K., Toda T., Tomiyama H., Uitti R.J., van Broeckhoven C., Wirdefeldt K., Wszolek Z., Xiromerisiou G., Yomono H.S., Yueh K.C., Zhao Y., Gasser T., Maraganore D., Kr\u00fcger R. (2012) A multi-centre clinico-genetic analysis of the VPS35 gene in Parkinson disease indicates reduced penetrance for disease-associated variants. J. Med. Genet., 49(11), 721\u2013726.","DOI":"10.1136\/jmedgenet-2012-101155"},{"key":"ref38","doi-asserted-by":"publisher","unstructured":"Chen X., Kordich J.K., Williams E.T., Levine N., Cole-Strauss A., Marshall L., Labrie V., Ma J., Lipton J.W., Moore D.J. (2019) Parkinson\u2019s disease-linked D620N VPS35 knockin mice manifest tau neuropathology and dopaminergic neurodegeneration. Proc. Natl. Acad. Sci. USA, 116(12), 5765\u20135774.","DOI":"10.1073\/pnas.1814909116"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"Tsika E., Glauser L., Moser R., Fiser A., Daniel G., Sheerin U.-M., Lees A., Troncoso J.C., Lewis P.A., Bandopadhyay R., Schneider B.L., Moore D.J. (2014) Parkinson\u2019s disease-linked mutations in VPS35 induce dopaminergic neurodegeneration. Hum. Mol. Genet., 23(17), 4621\u20134638.","DOI":"10.1093\/hmg\/ddu178"},{"key":"ref40","doi-asserted-by":"publisher","unstructured":"Paravicini G., Horazdovsky B.F., Emr S.D. (1992) Alternative pathways for the sorting of soluble vacuolar proteins in yeast: a vps35 null mutant missorts and secretes only a subset of vacuolar hydrolases. Mol. Biol. Cell, 3(4), 415\u2013427.","DOI":"10.1091\/mbc.3.4.415"},{"key":"ref41","doi-asserted-by":"publisher","unstructured":"Seaman M.N., McCaffery J.M., Emr S.D. (1998) A membrane coat complex essential for endosome-to-Golgi retrograde transport in yeast. J. Cell Biol., 142(3), 665\u2013681.","DOI":"10.1083\/jcb.142.3.665"},{"key":"ref42","doi-asserted-by":"publisher","unstructured":"Hierro A., Rojas A.L., Rojas R., Murthy N., Effantin G., Kajava A.V., Steven A.C., Bonifacino J.S., Hurley J.H. (2007) Functional architecture of the retromer cargo-recognition complex. Nature, 449(7165), 1063\u20131067.","DOI":"10.1038\/nature06216"},{"key":"ref43","doi-asserted-by":"publisher","unstructured":"Gokool S., Tattersall D., Reddy J.V., Seaman M.N.J. (2007) Identification of a conserved motif required for Vps35p\/Vps26p interaction and assembly of the retromer complex. Biochem. J., 408(2), 287\u2013295.","DOI":"10.1042\/BJ20070555"},{"key":"ref44","doi-asserted-by":"publisher","unstructured":"Collins B.M., Norwood S.J., Kerr M.C., Mahony D., Seaman M.N.J., Teasdale R.D., Owen D.J. (2008) Structure of Vps26B and mapping of its interaction with the retromer protein complex. Traffic, 9(3), 366\u2013379.","DOI":"10.1111\/j.1600-0854.2007.00688.x"},{"key":"ref45","doi-asserted-by":"publisher","unstructured":"Collins B.M., Skinner C.F., Watson P.J., Seaman M.N.J., Owen D.J. (2005) Vps29 has a phosphoesterase fold that acts as a protein interaction scaffold for retromer assembly. Nat. Struct. Mol. Biol., 12(7), 594\u2013602.","DOI":"10.1038\/nsmb954"},{"key":"ref46","doi-asserted-by":"publisher","unstructured":"Shi H., Rojas R., Bonifacino J.S., Hurley J.H. (2006) The retromer subunit Vps26 has an arrestin fold and binds Vps35 through its C-terminal domain. Nat. Struct. Mol. Biol., 13(6), 540\u2013548.","DOI":"10.1038\/nsmb1103"},{"key":"ref47","doi-asserted-by":"publisher","unstructured":"Lucas M., Gershlick D.C., Vidaurrazaga A., Rojas A.L., Bonifacino J.S., Hierro A. (2016) Structural mechanism for cargo recognition by the retromer complex. Cell, 167(6), 1623\u20131635.e14.","DOI":"10.1016\/j.cell.2016.10.056"},{"key":"ref48","doi-asserted-by":"publisher","unstructured":"Kim E., Lee Y., Lee H.-J., Kim J.S., Song B.-S., Huh J.-W., Lee S.-R., Kim S.-U., Kim S.-H., Hong Y., Shim I., Chang K.-T. (2010) Implication of mouse Vps26b-Vps29-Vps35 retromer complex in sortilin trafficking. Biochem. Biophys. Res. Commun., 403(2), 167\u2013171.","DOI":"10.1016\/j.bbrc.2010.10.121"},{"key":"ref49","doi-asserted-by":"publisher","unstructured":"Bugarcic A., Zhe Y., Kerr M.C., Griffin J., Collins B.M., Teasdale R.D. (2011) Vps26A and Vps26B subunits define distinct retromer complexes. Traffic, 12(12), 1759\u20131773.","DOI":"10.1111\/j.1600-0854.2011.01284.x"},{"key":"ref50","doi-asserted-by":"publisher","unstructured":"Bugarcic A., Vetter I., Chalmers S., Kinna G., Collins B.M., Teasdale R.D. (2015) Vps26B-retromer negatively regulates plasma membrane resensitization of PAR-2. Cell Biol. Int., 39(11), 1299\u20131306.","DOI":"10.1002\/cbin.10508"},{"key":"ref51","doi-asserted-by":"publisher","unstructured":"Kerr M.C., Bennetts J.S., Simpson F., Thomas E.C., Flegg C., Gleeson P.A., Wicking C., Teasdale R.D. (2005) A novel mammalian retromer component, Vps26B. Traffic, 6(11), 991\u20131001.","DOI":"10.1111\/j.1600-0854.2005.00328.x"},{"key":"ref52","doi-asserted-by":"publisher","unstructured":"Gallon M., Cullen P.J. (2015) Retromer and sorting nexins in endosomal sorting. Biochem. Soc. Trans., 43(1), 33\u201347.","DOI":"10.1042\/BST20140290"},{"key":"ref53","doi-asserted-by":"publisher","unstructured":"Bonifacino J.S., Hurley J.H. (2008) Retromer. Curr. Opin. Cell Biol., 20(4), 427\u2013436.","DOI":"10.1016\/j.ceb.2008.03.009"},{"key":"ref54","doi-asserted-by":"publisher","unstructured":"Cullen P.J., Korswagen H.C. (2012) Sorting nexins provide diversity for retromer-dependent trafficking events. Nat. Cell Biol., 14(1), 29\u201337.","DOI":"10.1038\/ncb2374"},{"key":"ref55","doi-asserted-by":"publisher","unstructured":"Seaman M.N.J. (2021) The retromer complex: from genesis to revelations. Trends Biochem. Sci., 46(7), 608\u2013620.","DOI":"10.1016\/j.tibs.2020.12.009"},{"key":"ref56","doi-asserted-by":"publisher","unstructured":"Wang J., Fedoseienko A., Chen B., Burstein E., Jia D., Billadeau D.D. (2018) Endosomal receptor trafficking: retromer and beyond. Traffic, 19(8), 578\u2013590.","DOI":"10.1111\/tra.12574"},{"key":"ref57","doi-asserted-by":"publisher","unstructured":"Carosi J.M., Denton D., Kumar S., Sargeant T.J. (2023) Receptor recycling by retromer. Mol. Cell. Biol., 43(7), 317\u2013334.","DOI":"10.1080\/10985549.2023.2222053"},{"key":"ref58","doi-asserted-by":"publisher","unstructured":"Cui Y., Yang Z., Teasdale R.D. (2018) The functional roles of retromer in Parkinson\u2019s disease. FEBS Lett., 592(7), 1096\u20131112.","DOI":"10.1002\/1873-3468.12931"},{"key":"ref59","doi-asserted-by":"publisher","unstructured":"Fokin A.I., Gautreau A.M. (2021) Assembly and activity of the WASH molecular machine: distinctive features at the crossroads of the actin and microtubule cytoskeletons. Front. Cell Dev. Biol., 9, 658865.","DOI":"10.3389\/fcell.2021.658865"},{"key":"ref60","doi-asserted-by":"publisher","unstructured":"Ryder P.V., Vistein R., Gokhale A., Seaman M.N., Puthenveedu M.A., Faundez V. (2013) The WASH complex, an endosomal Arp2\/3 activator, interacts with the Hermansky-Pudlak syndrome complex BLOC-1 and its cargo phosphatidylinositol-4-kinase type II\u03b1. Mol. Biol. Cell, 24(14), 2269\u20132284.","DOI":"10.1091\/mbc.E13-02-0088"},{"key":"ref61","doi-asserted-by":"publisher","unstructured":"Romano-Moreno M., Astorga-Simyn E.N., Rojas A.L., Hierro A. (2024) Retromer-mediated recruitment of the WASH complex involves discrete interactions between VPS35, VPS29, and FAM21. Protein Sci., 33(5), e4980.","DOI":"10.1002\/pro.4980"},{"key":"ref62","doi-asserted-by":"publisher","unstructured":"Dost\u00e1l V., Humhalov\u00e1 T., Ber\u00e1nkov\u00e1 P., P\u00e1calt O., Libusov\u00e1 L. (2023) SWIP mediates retromer-independent membrane recruitment of the WASH complex. Traffic, 24(5), 216\u2013230.","DOI":"10.1111\/tra.12884"},{"key":"ref63","doi-asserted-by":"publisher","unstructured":"Zavodszky E., Seaman M.N.J., Moreau K., Jimenez-Sanchez M., Breusegem S.Y., Harbour M.E., Rubinsztein D.C. (2014) Mutation in VPS35 associated with Parkinson\u2019s disease impairs WASH complex association and inhibits autophagy. Nat. Commun., 5, 3828.","DOI":"10.1038\/ncomms4828"},{"key":"ref64","doi-asserted-by":"publisher","unstructured":"Follett J., Norwood S.J., Hamilton N.A., Mohan M., Kovtun O., Tay S., Zhe Y., Wood S.A., Mellick G.D., Silburn P.A., Collins B.M., Bugarcic A., Teasdale R.D. (2014) The Vps35 D620N mutation linked to Parkinson's disease disrupts the cargo sorting function of retromer. Traffic, 15(2), 230\u2013244.","DOI":"10.1111\/tra.12136"},{"key":"ref65","doi-asserted-by":"publisher","unstructured":"Fan X., Xie Y., Cao S., Zhu L., Wang X. (2025) VPS35-retromer: multifunctional roles in various biological processes \u2014 a focus on neurodegenerative diseases and cancer. J. Inflamm. Res., 18, 4665\u20134680.","DOI":"10.2147\/JIR.S510768"},{"key":"ref66","doi-asserted-by":"publisher","unstructured":"Ba\u00f1os-Mateos S., Rojas A.L., Hierro A. (2019) VPS29, a tweak tool of endosomal recycling. Curr. Opin. Cell Biol., 59, 81\u201387.","DOI":"10.1016\/j.ceb.2019.03.010"},{"key":"ref67","doi-asserted-by":"publisher","unstructured":"Shannon B., Soto-Ortolaza A., Rayaprolu S., Cannon H.D., Labb\u00e9 C., Benitez Bruno.A., Choi J., Lynch T., Boczarska-Jedynak M., Opala G., Krygowska-Wajs A., Barcikowska M., van Gerpen J.A., Uitti R.J., Springer W., Cruchaga C., Wszolek Z.K., Ross O.A. (2014) Genetic variation of the retromer subunits VPS26A\/B-VPS29 in Parkinson\u2019s disease. Neurobiol. Aging, 35(8), 1958.e1\u2013e2.","DOI":"10.1016\/j.neurobiolaging.2014.03.004"},{"key":"ref68","doi-asserted-by":"publisher","unstructured":"Seong J.B., Kim Y.-H., Huh J.-W., Lee Y. (2023) VPS26b plays a protective role against MPP+-induced neurotoxicity in dopaminergic SH-SY5Y cells. IBRO Neurosci. Rep., 15(Suppl 1), S203.","DOI":"10.1016\/j.ibneur.2023.08.317"},{"key":"ref69","doi-asserted-by":"publisher","unstructured":"Buneeva O., Kopylov A., Kapitsa I., Ivanova E., Zgoda V., Medvedev A. (2018) The effect of neurotoxin MPTP and neuroprotector isatin on the profile of ubiquitinated brain mitochondrial proteins. Cells, 7(8), 91.","DOI":"10.3390\/cells7080091"},{"key":"ref70","doi-asserted-by":"publisher","unstructured":"Buneeva O., Fedchenko V., Kopylov A., Medvedev A. (2020) Mitochondrial dysfunction in Parkinson\u2019s disease: focus on mitochondrial DNA. Biomedicines, 8(12), 591.","DOI":"10.3390\/biomedicines8120591"},{"key":"ref71","doi-asserted-by":"publisher","unstructured":"Hattori N., Sato S. (2024) Mitochondrial dysfunction in Parkinson\u2019s disease. J. Neural Transm. (Vienna), 131(12), 1415\u20131428.","DOI":"10.1007\/s00702-024-02863-2"},{"key":"ref72","doi-asserted-by":"publisher","unstructured":"Moon H.E., Paek S.H. (2015) Mitochondrial dysfunction in Parkinson\u2019s disease. Exp. Neurobiol., 24(2), 103\u2013116.","DOI":"10.5607\/en.2015.24.2.103"},{"key":"ref73","doi-asserted-by":"publisher","unstructured":"Ammal Kaidery N., Thomas B. (2018) Current perspective of mitochondrial biology in Parkinson\u2019s disease. Neurochem. Int., 117, 91\u2013113.","DOI":"10.1016\/j.neuint.2018.03.001"},{"key":"ref74","doi-asserted-by":"publisher","unstructured":"Rey F., Ottolenghi S., Zuccotti G.V., Samaja M., Carelli S. (2022) Mitochondrial dysfunctions in neurodegenerative diseases: role in disease pathogenesis, strategies for analysis and therapeutic prospects. Neural Regen. Res., 17(4), 754\u2013758.","DOI":"10.4103\/1673-5374.322430"},{"key":"ref75","doi-asserted-by":"publisher","unstructured":"Rossi A., Pizzo P., Filadi R. (2019) Calcium, mitochondria and cell metabolism: a functional triangle in bioenergetics. Biochim. Biophys. Acta Mol. Cell Res., 1866(7), 1068\u20131078.","DOI":"10.1016\/j.bbamcr.2018.10.016"},{"key":"ref76","doi-asserted-by":"publisher","unstructured":"Tait S.W.G., Green D.R. (2012) Mitochondria and cell signalling. J. Cell Sci., 125(Pt 4), 807\u2013815.","DOI":"10.1242\/jcs.099234"},{"key":"ref77","doi-asserted-by":"publisher","unstructured":"Chakrabarty R.P., Chandel N.S. (2022) Beyond ATP, new roles of mitochondria. Biochemist (London), 44(4), 2\u20138.","DOI":"10.1042\/bio_2022_119"},{"key":"ref78","doi-asserted-by":"publisher","unstructured":"Spinelli J.B., Haigis M.C. (2018) The multifaceted contributions of mitochondria to cellular metabolism. Nat. Cell Biol., 20(7), 745\u2013754.","DOI":"10.1038\/s41556-018-0124-1"},{"key":"ref79","doi-asserted-by":"publisher","unstructured":"Buneeva O., Medvedev A. (2025) Monoamine oxidase inhibitors in toxic models of Parkinsonism. Int. J. Mol. Sci., 26(3), 1248.","DOI":"10.3390\/ijms26031248"},{"key":"ref80","doi-asserted-by":"publisher","unstructured":"Glinka Y.Y., Youdim M.B. (1995) Inhibition of mitochondrial complexes I and IV by 6-hydroxydopamine. Eur. J. Pharmacol., 292(3\u20134), 329\u2013332.","DOI":"10.1016\/0926-6917(95)90040-3"},{"key":"ref81","doi-asserted-by":"publisher","unstructured":"Langston J.W. (2017) The MPTP story. J. Parkinsons Dis., 7(s1), S11\u2013S19.","DOI":"10.3233\/JPD-179006"},{"key":"ref82","doi-asserted-by":"publisher","unstructured":"Subhan I., Siddique Y.H. (2024) Effect of rotenone on the neurodegeneration among different models. Curr. Drug Targets, 25(8), 530\u2013542.","DOI":"10.2174\/0113894501281496231226070459"},{"key":"ref83","doi-asserted-by":"publisher","unstructured":"Betarbet R., Canet-Aviles R.M., Sherer T.B., Mastroberardino P.G., McLendon C., Kim J.-H., Lund S., Na H.-M., Taylor G., Bence N.F., Kopito R., Seo B.B., Yagi T., Yagi A., Klinefelter G., Cookson M.R., Greenamyre J.T. (2006) Intersecting pathways to neurodegeneration in Parkinson\u2019s disease: effects of the pesticide rotenone on DJ-1, \u03b1-synuclein, and the ubiquitin-proteasome system. Neurobiol. Dis., 22(2), 404\u2013420.","DOI":"10.1016\/j.nbd.2005.12.003"},{"key":"ref84","doi-asserted-by":"publisher","unstructured":"Elmorsy E., Al-Ghafari A., Al Doghaither H., Hashish S., Salama M., Mudyanselage A.W., James L., Carter W.G. (2023) Differential effects of paraquat, rotenone, and MPTP on cellular bioenergetics of undifferentiated and differentiated human neuroblastoma cells. Brain Sci., 13(12), 1717.","DOI":"10.3390\/brainsci13121717"},{"key":"ref85","doi-asserted-by":"publisher","unstructured":"Vare\u0161lija D., Tipton K.F., Davey G.P., McDonald A.G. (2020) 6-Hydroxydopamine: a far from simple neurotoxin. J. Neural Transm. (Vienna), 127(2), 213\u2013230.","DOI":"10.1007\/s00702-019-02133-6"},{"key":"ref86","doi-asserted-by":"publisher","unstructured":"Bi F., Li F., Huang C., Zhou H. (2013) Pathogenic mutation in VPS35 impairs its protection against MPP+ cytotoxicity. Int. J. Biol. Sci., 9(2), 149\u2013155.","DOI":"10.7150\/ijbs.5617"},{"key":"ref87","doi-asserted-by":"publisher","unstructured":"Hanss Z., Larsen S.B., Antony P., Mencke P., Massart F., Jarazo J., Schwamborn J.C., Barbuti P.A., Mellick G.D., Kr\u00fcger R. (2021) Mitochondrial and clearance impairment in p.D620N VPS35 patient-derived neurons. Mov. Disord., 36(3), 704\u2013715.","DOI":"10.1002\/mds.28365"},{"key":"ref88","doi-asserted-by":"publisher","unstructured":"Bertholet A.M., Delerue T., Millet A.M., Moulis M.F., David C., Daloyau M., Arnaun\u00e9-Pelloquin L., Davezac N., Mils V., Miquel M.C., Rojo M., Belenguer P. (2016) Mitochondrial fusion\/fission dynamics in neurodegeneration and neuronal plasticity. Neurobiol. Dis., 90, 3\u201319.","DOI":"10.1016\/j.nbd.2015.10.011"},{"key":"ref89","doi-asserted-by":"publisher","unstructured":"Yang D., Ying J., Wang X., Zhao T., Yoon S., Fang Y., Zheng Q., Liu X., Yu W., Hua F. (2021) Mitochondrial dynamics: a key role in neurodegeneration and a potential target for neurodegenerative disease. Front. Neurosci., 15, 654785.","DOI":"10.3389\/fnins.2021.654785"},{"key":"ref90","doi-asserted-by":"publisher","unstructured":"Pellegrini L., Wetzel A., Granny S., Heaton G., Harvey K. (2016) Back to the tubule: microtubule dynamics in Parkinson\u2019s disease. Cell. Mol. Life Sci., 74(3), 409\u2013434.","DOI":"10.1007\/s00018-016-2351-6"},{"key":"ref91","doi-asserted-by":"publisher","unstructured":"Yapa N.M.B., Lisnyak V., Reljic B., Ryan M.T. (2021) Mitochondrial dynamics in health and disease. FEBS Lett., 595(8),1184\u20131204.","DOI":"10.1002\/1873-3468.14077"},{"key":"ref92","doi-asserted-by":"publisher","unstructured":"Grel H., Woznica D., Ratajczak K., Kalwarczyk E., Anchimowicz J., Switlik W., Olejnik P., Zielonka P., Stobiecka M., Jakiela S. (2023) Mitochondrial dynamics in neurodegenerative diseases: unraveling the role of fusion and fission processes. Int. J. Mol. Sci., 24(17), 13033.","DOI":"10.3390\/ijms241713033"},{"key":"ref93","doi-asserted-by":"publisher","unstructured":"Guan D., Liang C., Zheng D., Liu S., Luo J., Cai Z., Zhang H., Chen J. (2025) The role of mitochondrial remodeling in neurodegenerative diseases. Neurochem. Int., 183, 105927.","DOI":"10.1016\/j.neuint.2024.105927"},{"key":"ref94","doi-asserted-by":"publisher","unstructured":"Braschi E., Goyon V., Zunino R., Mohanty A., Xu L., McBride H.M. (2010) Vps35 mediates vesicle transport between the mitochondria and peroxisomes. Curr. Biol., 20(14), 1310\u20131315.","DOI":"10.1016\/j.cub.2010.05.066"},{"key":"ref95","doi-asserted-by":"publisher","unstructured":"Soubannier V., McLelland G.-L., Zunino R., Braschi E., Rippstein P., Fon E.A., McBride H.M. (2012) A vesicular transport pathway shuttles cargo from mitochondria to lysosomes. Curr. Biol., 22(2), 135\u2013141.","DOI":"10.1016\/j.cub.2011.11.057"},{"key":"ref96","doi-asserted-by":"publisher","unstructured":"Sugiura A., McLelland G., Fon E.A., McBride H.M. (2014) A new pathway for mitochondrial quality control: mitochondrial-derived vesicles. EMBO J., 33(19), 2142\u20132156.","DOI":"10.15252\/embj.201488104"},{"key":"ref97","doi-asserted-by":"publisher","unstructured":"Koyano F., Yamano K., Kosako H., Kimura Y., Kimura M., Fujiki Y., Tanaka K., Matsuda N. (2019) Parkin-mediated ubiquitylation redistributes MITOL\/March5 from mitochondria to peroxisomes. EMBO Rep., 20(12), e47728.","DOI":"10.15252\/embr.201947728"},{"key":"ref98","doi-asserted-by":"publisher","unstructured":"Wang W., Wang X., Fujioka H., Hoppel C., Whone A.L., Caldwell M.A., Cullen P.J., Liu J., Zhu X. (2016) Parkinson\u2019s disease-associated mutant VPS35 causes mitochondrial dysfunction by recycling DLP1 complexes. Nat. Med., 22(1), 54\u201363.","DOI":"10.1038\/nm.3983"},{"key":"ref99","doi-asserted-by":"publisher","unstructured":"Lu B. (2009) Mitochondrial dynamics and neurodegeneration. Curr. Neurol. Neurosci. Rep., 9(3), 212\u2013219.","DOI":"10.1007\/s11910-009-0032-7"},{"key":"ref100","doi-asserted-by":"publisher","unstructured":"Itoh K., Nakamura K., Iijima M., Sesaki H. (2013) Mitochondrial dynamics in neurodegeneration. Trends Cell Biol., 23(2), 64\u201371.","DOI":"10.1016\/j.tcb.2012.10.006"},{"key":"ref101","doi-asserted-by":"publisher","unstructured":"Smirnova E., Griparic L., Shurland D.-L., van der Bliek A.M. (2001) Dynamin-related protein Drp1 is required for mitochondrial division in mammalian cells. Mol. Biol. Cell, 12(8), 2245\u20132256.","DOI":"10.1091\/mbc.12.8.2245"},{"key":"ref102","doi-asserted-by":"publisher","unstructured":"Song Z., Ghochani M., McCaffery J.M., Frey T.G., Chan D.C. (2009) Mitofusins and OPA1 mediate sequential steps in mitochondrial membrane fusion. Mol. Biol. Cell, 20(15), 3525\u20133532.","DOI":"10.1091\/mbc.E09-03-0252"},{"key":"ref103","doi-asserted-by":"publisher","unstructured":"Tang F.-L., Liu W., Hu J.-X., Erion J.R., Ye J., Mei L., Xiong W.-C. (2015) VPS35 deficiency or mutation causes dopaminergic neuronal loss by impairing mitochondrial fusion and function. Cell Rep., 12(10), 1631\u20131643.","DOI":"10.1016\/j.celrep.2015.08.001"},{"key":"ref104","doi-asserted-by":"publisher","unstructured":"Wang W., Ma X., Zhou L., Liu J., Zhu X. (2017) A conserved retromer sorting motif is essential for mitochondrial DLP1 recycling by VPS35 in Parkinson\u2019s disease model. Hum. Mol. Genet., 26(4), 781\u2013789.","DOI":"10.1093\/hmg\/ddw430"},{"key":"ref105","doi-asserted-by":"publisher","unstructured":"Wang X.-L., Feng S.-T., Wang Y.-T., Yuan Y.-H., Li Z.-P., Chen N.-H., Wang Z.-Z., Zhang Y. (2022) Mitophagy, a form of selective autophagy, plays an essential role in mitochondrial dynamics of Parkinson\u2019s disease. Cell. Mol. Neurobiol., 42 (5), 1321\u20131339.","DOI":"10.1007\/s10571-021-01039-w"},{"key":"ref106","doi-asserted-by":"publisher","unstructured":"Cutillo G., Simon D.K., Eleuteri S. (2020) VPS35 and the mitochondria: connecting the dots in Parkinson\u2019s disease pathophysiology. Neurobiol. Dis., 145, 105056.","DOI":"10.1016\/j.nbd.2020.105056"},{"key":"ref107","doi-asserted-by":"publisher","unstructured":"Olszewska D.A., McCarthy A., Lynch T. (2016) Commentary: Parkinson\u2019s disease genes VPS35 and EIF4G1 interact genetically and converge on \u03b1-synuclein. Front. Neurosci., 10, 162.","DOI":"10.3389\/fnins.2016.00162"},{"key":"ref108","doi-asserted-by":"publisher","unstructured":"Rowlands J., Moore D.J. (2024) VPS35 and retromer dysfunction in Parkinson\u2019s disease. Philos. Trans. R. Soc. Lond. B. Biol. Sci., 379, 20220384.","DOI":"10.1098\/rstb.2022.0384"},{"key":"ref109","doi-asserted-by":"publisher","unstructured":"Ostrerova N., Petrucelli L., Farrer M., Mehta N., Choi P., Hardy J., Wolozin B. (1999) \u03b1-Synuclein shares physical and functional homology with 14-3-3 proteins. J. Neurosci., 19(14), 5782\u20135791.","DOI":"10.1523\/JNEUROSCI.19-14-05782.1999"},{"key":"ref110","doi-asserted-by":"publisher","unstructured":"Tran H.L., Zheng W., Issadore D.A., Im H., Cho Y.-K., Zhang Y., Liu D., Liu Y., Li B., Liu F., Wong D.T.W., Sun J., Qian K., He M., Wan M., Zeng Y., Cheng K., Huang T.J., Chiu D.T., Lee L.P., Zheng L., Godwin A.K., Kalluri R., Soper S.A., Hu T.Y. (2025) Extracellular vesicles for clinical diagnostics: from bulk measurements to single-vesicle analysis. ACS Nano, 19(31), 28021\u201328109.","DOI":"10.1021\/acsnano.5c00706"},{"key":"ref111","doi-asserted-by":"publisher","unstructured":"Ryan B.J., Hoek S., Fon E.A., Wade-Martins R. (2015) Mitochondrial dysfunction and mitophagy in Parkinson\u2019s: from familial to sporadic disease. Trends Biochem. Sci., 40(4), 200\u2013210.","DOI":"10.1016\/j.tibs.2015.02.003"},{"key":"ref112","doi-asserted-by":"publisher","unstructured":"Sohrabi T., Mirzaei-Behbahani B., Zadali R., Pirhaghi M., Morozova-Roche L.A., Meratan A.A. (2023) Common mechanisms underlying \u03b1-synuclein-induced mitochondrial dysfunction in Parkinson\u2019s disease. J. Mol. Biol., 435(12), 167992.","DOI":"10.1016\/j.jmb.2023.167992"},{"key":"ref113","doi-asserted-by":"publisher","unstructured":"Guardia-Laguarta C., Area-Gomez E., R\u00fcb C., Liu Y., Magran\u00e9 J., Becker D., Voos W., Schon E.A., Przedborski S. (2014) \u03b1-Synuclein is localized to mitochondria-associated ER membranes. J. Neurosci., 34(1), 249\u2013259.","DOI":"10.1523\/JNEUROSCI.2507-13.2014"},{"key":"ref114","doi-asserted-by":"publisher","unstructured":"Chinta S.J., Mallajosyula J.K., Rane A., Andersen J.K. (2010) Mitochondrial alpha-synuclein accumulation impairs complex I function in dopaminergic neurons and results in increased mitophagy in vivo. Neurosci. Lett., 486(3), 235\u2013239.","DOI":"10.1016\/j.neulet.2010.09.061"},{"key":"ref115","doi-asserted-by":"publisher","unstructured":"Reeve A.K., Ludtmann M.H., Angelova P.R., Simcox E.M., Horrocks M.H., Klenerman D., Gandhi S., Turnbull D.M., Abramov A.Y. (2015) Aggregated \u03b1-synuclein and complex I deficiency: exploration of their relationship in differentiated neurons. Cell Death Dis., 6(7), e1820.","DOI":"10.1038\/cddis.2015.166"},{"key":"ref116","doi-asserted-by":"publisher","unstructured":"Erustes A.G., Guarache G.C., Guedes E.D.C., Le\u00e3o A.H.F.F., Pereira G.J.D.S., Smaili S.S. (2022) \u03b1-Synuclein interactions in mitochondria-ER contacts: a possible role in Parkinson\u2019s disease. Contact, 5, 25152564221119347.","DOI":"10.1177\/25152564221119347"},{"key":"ref117","doi-asserted-by":"publisher","unstructured":"Geibl F.F., Henrich M.T., Xie Z., Zampese E., Ueda J., Tkatch T., Wokosin D.L., Nasiri E., Grotmann C.A., Dawson V.L., Dawson T.M., Chandel N.S., Oertel W.H., Surmeier D.J. (2024) \u03b1-Synuclein pathology disrupts mitochondrial function in dopaminergic and cholinergic neurons at-risk in Parkinson\u2019s disease. Mol. Neurodegener., 19, 69.","DOI":"10.1186\/s13024-024-00756-2"},{"key":"ref118","doi-asserted-by":"publisher","unstructured":"Shen L., Dettmer U. (2024) Alpha-synuclein effects on mitochondrial quality control in Parkinson\u2019s disease. Biomolecules, 14(12), 1649.","DOI":"10.3390\/biom14121649"},{"key":"ref119","doi-asserted-by":"publisher","unstructured":"Ganjam G.K., Bolte K., Matschke L.A., Neitemeier S., Dolga A.M., H\u00f6llerhage M., H\u00f6glinger G.U., Adamczyk A., Decher N., Oertel W.H., Culmsee C. (2019) Mitochondrial damage by \u03b1-synuclein causes cell death in human dopaminergic neurons. Cell Death Dis., 10(11), 865.","DOI":"10.1038\/s41419-019-2091-2"},{"key":"ref120","doi-asserted-by":"publisher","unstructured":"Liu Z., Shan S., Kang K., Wang S., Yong H., Sun Y., Bai Y., Song F. (2024) Mitochondrial transfer of \u03b1-synuclein mediates carbon disulfide-induced mitochondrial dysfunction and neurotoxicity. Ecotoxicol. Environ. Saf., 281, 116613.","DOI":"10.1016\/j.ecoenv.2024.116613"},{"key":"ref121","doi-asserted-by":"publisher","unstructured":"Vasquez V., Kodavati M., Mitra J., Vedula I., Hamilton D.J., Garruto R.M., Rao K.S., Hegde M.L. (2024) Mitochondria-targeted oligomeric \u03b1-synuclein induces TOM40 degradation and mitochondrial dysfunction in Parkinson\u2019s disease and parkinsonism-dementia of Guam. Cell Death Dis., 15(12), 914.","DOI":"10.1038\/s41419-024-07258-5"},{"key":"ref122","doi-asserted-by":"publisher","unstructured":"Gezen-Ak D., Yurtta\u015f Z., \u00c7amo\u01e7lu T., Dursun E (2022) Could amyloid-\u03b2 1\u201342 or \u03b1-synuclein interact directly with mitochondrial DNA? A hypothesis. ACS Chemical Neurosci., 13(19), 2803\u20132812.","DOI":"10.1021\/acschemneuro.2c00512"},{"key":"ref123","doi-asserted-by":"publisher","unstructured":"Dhungel N., Eleuteri S., Li L.-B., Kramer N.J., Chartron J.W., Spencer B., Kosberg K., Fields J.A., Stafa K., Adame A., Lashuel H., Frydman J., Shen K., Masliah E., Gitler A.D. (2015) Parkinson\u2019s disease genes VPS35 and EIF4G1 interact genetically and converge on \u03b1-synuclein. Neuron, 85(1), 76\u201387.","DOI":"10.1016\/j.neuron.2014.11.027"},{"key":"ref124","doi-asserted-by":"publisher","unstructured":"Fu C., Yang N., Chuang J.-Z., Nakajima N., Iraha S., Roy N., Wu Z., Jiang Z., Otsu W., Radu R.A., Yang H.H., Lee M.P., Worgall T.S., Xiong W.-C., Sung C.-H. (2024) Mutant mice with rod-specific VPS35 deletion exhibit retinal \u03b1-synuclein pathology-associated degeneration. Nat. Commun., 15, 5970.","DOI":"10.1038\/s41467-024-50189-0"},{"key":"ref125","doi-asserted-by":"publisher","unstructured":"Lu J., Wu M., Yue Z. (2020) Autophagy and Parkinson\u2019s disease. Adv. Exp. Med. Biol., 1207, 21\u201351.","DOI":"10.1007\/978-981-15-4272-5_2"},{"key":"ref126","doi-asserted-by":"publisher","unstructured":"Sironi L., Restelli L.M., Tolnay M., Neutzner A., Frank S. (2020) Dysregulated interorganellar crosstalk of mitochondria in the pathogenesis of Parkinson\u2019s disease. Cells, 9(1), 233.","DOI":"10.3390\/cells9010233"},{"key":"ref127","doi-asserted-by":"publisher","unstructured":"Bono K., Hara-Miyauchi C., Sumi S., Oka H., Iguchi Y., Okano H.J. (2020) Endosomal dysfunction in iPSC-derived neural cells from Parkinson\u2019s disease patients with VPS35 D620N. Mol. Brain, 13, 137.","DOI":"10.1186\/s13041-020-00675-5"},{"key":"ref128","doi-asserted-by":"publisher","unstructured":"Tang F.-L., Erion J.R., Tian Y., Liu W., Yin D.-M., Ye J., Tang B., Mei L., Xiong W.-C. (2015) VPS35 in dopamine neurons is required for endosome-to-Golgi retrieval of Lamp2a, a receptor of chaperone-mediated autophagy that is critical for \u03b1-synuclein degradation and prevention of pathogenesis of Parkinson\u2019s disease. J. Neurosci., 35(29), 10613\u201310628.","DOI":"10.1523\/JNEUROSCI.0042-15.2015"},{"key":"ref129","doi-asserted-by":"publisher","unstructured":"Miura E., Hasegawa T., Konno M., Suzuki M., Sugeno N., Fujikake N., Geisler S., Tabuchi M., Oshima R., Kikuchi A., Baba T., Wada K., Nagai Y., Takeda A., Aoki M. (2014) VPS35 dysfunction impairs lysosomal degradation of \u03b1-synuclein and exacerbates neurotoxicity in a Drosophila model of Parkinson\u2019s disease. Neurobiol. Dis., 71, 1\u201313.","DOI":"10.1016\/j.nbd.2014.07.014"},{"key":"ref130","doi-asserted-by":"publisher","unstructured":"Chen X., Tsika E., Levine N., Moore D.J. (2023) VPS35 and \u03b1-synuclein fail to interact to modulate neurodegeneration in rodent models of Parkinson\u2019s disease. Mol. Neurodegener., 18, 51.","DOI":"10.1186\/s13024-023-00641-4"},{"key":"ref131","doi-asserted-by":"publisher","unstructured":"Niu M., Zhao F., Bondelid K., Siedlak S.L., Torres S., Fujioka H., Wang W., Liu J., Zhu X. (2021) VPS35 D620N knockin mice recapitulate cardinal features of Parkinson\u2019s disease. Aging Cell, 20(5), e13347.","DOI":"10.1111\/acel.13347"},{"key":"ref132","doi-asserted-by":"publisher","unstructured":"Lin K.-J., Lin K.-L., Chen S.-D., Liou C.-W., Chuang Y.-C., Lin H.-Y., Lin T.-K. (2019) The overcrowded crossroads: mitochondria, alpha-synuclein, and the endo-lysosomal system interaction in Parkinson\u2019s disease. Int. J. Mol. Sci., 20(21), 5312.","DOI":"10.3390\/ijms20215312"},{"key":"ref133","doi-asserted-by":"publisher","unstructured":"Pozo Devoto V.M., Falzone T.L. (2017) Mitochondrial dynamics in Parkinson\u2019s disease: a role for \u03b1-synuclein? Dis. Model. Mech., 10(9), 1075\u20131087.","DOI":"10.1242\/dmm.026294"},{"key":"ref134","doi-asserted-by":"publisher","unstructured":"Follett J., Bugarcic A., Yang Z., Ariotti N., Norwood S.J., Collins B.M., Parton R.G., Teasdale R.D. (2016) Parkinson disease-linked Vps35 R524W mutation impairs the endosomal association of retromer and induces \u03b1-synuclein aggregation. J. Biol. Chem., 291(35), 18283\u201318298.","DOI":"10.1074\/jbc.M115.703157"},{"key":"ref135","doi-asserted-by":"publisher","unstructured":"Persico M., Fang T.S.Z., Tucci C., Simon D., Eleuteri S. (2024) Investigating the indirect interaction between Vps35 and \u03b1-synuclein in Parkinson\u2019s disease (S26.007). Neurology, 102(17 Supplement 1), DOI: 10.1212\/WNL.0000000000204465.","DOI":"10.1212\/WNL.0000000000204465"},{"key":"ref136","doi-asserted-by":"publisher","unstructured":"Villa N., Fraser C.S. (2024) Human eukaryotic initiation factor 4G directly binds the 40S ribosomal subunit to promote efficient translation. J. Biol. Chem., 300(5), 107242.","DOI":"10.1016\/j.jbc.2024.107242"},{"key":"ref137","doi-asserted-by":"publisher","unstructured":"Kim S.-H., Choi J.-H., Marsal-Garc\u00eda L., Amiri M., Yanagiya A., Sonenberg N. (2023) The mRNA translation initiation factor eIF4G1 controls mitochondrial oxidative phosphorylation, axonal morphogenesis, and memory. Proc. Natl. Acad. Sci. USA, 120(25), e2300008120.","DOI":"10.1073\/pnas.2300008120"},{"key":"ref138","doi-asserted-by":"publisher","unstructured":"Deng H., Gao K., Jankovic J. (2013) The VPS35 gene and Parkinson\u2019s disease. Mov. Disord., 28(5), 569\u2013575.","DOI":"10.1002\/mds.25430"},{"key":"ref139","doi-asserted-by":"publisher","unstructured":"Chartier-Harlin M.-C., Dachsel J.C., Vilari\u00f1o-G\u00fcell C., Lincoln S.J., Lepr\u00eatre F., Hulihan M.M., Kachergus J., Milnerwood A.J., Tapia L., Song M.-S., le Rhun E., Mutez E., Larvor L., Duflot A., Vanbesien-Mailliot C., Kreisler A., Ross O.A., Nishioka K., Soto-Ortolaza A.I., Cobb S.A., Melrose H.L., Behrouz B., Keeling B.H., Bacon J.A., Hentati E., Williams L., Yanagiya A., Sonenberg N., Lockhart P.J., Zubair A.C., Uitti R.J., Aasly J.O., Krygowska-Wajs A., Opala G., Wszolek Z.K., Frigerio R., Maraganore D.M., Gosal D., Lynch T., Hutchinson M., Bentivoglio A.R., Valente E.M., Nichols W.C., Pankratz N., Foroud T., Gibson R.A., Hentati F., Dickson D.W., Dest\u00e9e A., Farrer M.J. (2011) Translation initiator EIF4G1 mutations in familial Parkinson disease. Am. J. Hum. Genet., 89(3), 398\u2013406.","DOI":"10.1016\/j.ajhg.2011.08.009"},{"key":"ref140","doi-asserted-by":"publisher","unstructured":"Ando M., Fiesel F.C., Hudec R., Caulfield T.R., Ogaki K., G\u00f3rka-Skoczylas P., Koziorowski D., Friedman A., Chen L., Dawson V.L., Dawson T.M., Bu G., Ross O.A., Wszolek Z.K., Springer W. (2017) The PINK1 p.I368N mutation affects protein stability and ubiquitin kinase activity. Mol. Neurodegener., 12, 32.","DOI":"10.1186\/s13024-017-0174-z"},{"key":"ref141","doi-asserted-by":"publisher","unstructured":"Trempe J.-F., Gehring K. (2023) Structural mechanisms of mitochondrial quality control mediated by PINK1 and Parkin. J. Mol. Biol., 435(12), 168090.","DOI":"10.1016\/j.jmb.2023.168090"},{"key":"ref142","doi-asserted-by":"publisher","unstructured":"Ge P., Dawson V.L., Dawson T.M. (2020) PINK1 and Parkin mitochondrial quality control: a source of regional vulnerability in Parkinson\u2019s disease. Mol. Neurodegener., 15, 20.","DOI":"10.1186\/s13024-020-00367-7"},{"key":"ref143","doi-asserted-by":"publisher","unstructured":"K\u00f6nig T., McBride H.M. (2024) Mitochondrial-derived vesicles in metabolism, disease, and aging. Cell Metab., 36(1), 21\u201335.","DOI":"10.1016\/j.cmet.2023.11.014"},{"key":"ref144","doi-asserted-by":"publisher","unstructured":"Rakovic A., Gr\u00fcnewald A., Kottwitz J., Br\u00fcggemann N., Pramstaller P.P., Lohmann K., Klein C. (2011) Mutations in PINK1 and Parkin impair ubiquitination of mitofusins in human fibroblasts. PLOS One, 6(3), e16746.","DOI":"10.1371\/journal.pone.0016746"},{"key":"ref145","doi-asserted-by":"publisher","unstructured":"Yang Y., Ouyang Y., Yang L., Beal M.F., McQuibban A., Vogel H., Lu B. (2008) Pink1 regulates mitochondrial dynamics through interaction with the fission\/fusion machinery. Proc. Natl. Acad. Sci. USA, 105(19), 7070\u20137075.","DOI":"10.1073\/pnas.0711845105"},{"key":"ref146","doi-asserted-by":"publisher","unstructured":"Malik B.R., Godena V.K., Whitworth A.J. (2015) VPS35 pathogenic mutations confer no dominant toxicity but partial loss of function in Drosophila and genetically interact with parkin. Hum. Mol. Genet., 24(21), 6106\u20136117.","DOI":"10.1093\/hmg\/ddv322"},{"key":"ref147","doi-asserted-by":"publisher","unstructured":"Williams E.T., Glauser L., Tsika E., Jiang H., Islam S., Moore D.J. (2018) Parkin mediates the ubiquitination of VPS35 and modulates retromer-dependent endosomal sorting. Hum. Mol. Genet., 27(18), 3189\u20133205.","DOI":"10.1093\/hmg\/ddy224"},{"key":"ref148","doi-asserted-by":"publisher","unstructured":"Martinez A., Lectez B., Ramirez J., Popp O., Sutherland J.D., Urb\u00e9 S., Dittmar G., Clague M.J., Mayor U. (2017) Quantitative proteomic analysis of Parkin substrates in Drosophila neurons. Mol. Neurodegener., 12, 29.","DOI":"10.1186\/s13024-017-0170-3"},{"key":"ref149","doi-asserted-by":"publisher","unstructured":"Ma K.Y., Fokkens M.R., Reggiori F., Mari M., Verbeek D.S. (2021) Parkinson\u2019s disease-associated VPS35 mutant reduces mitochondrial membrane potential and impairs PINK1\/Parkin-mediated mitophagy. Transl. Neurodegener., 10, 19.","DOI":"10.1186\/s40035-021-00243-4"},{"key":"ref150","doi-asserted-by":"publisher","unstructured":"Buneeva O.A., Medvedev A.E. (2021) DJ-1 protein and its role in the development of Parkinson\u2019s disease: studies on experimental models. Biochemistry (Moscow), 86(6), 627\u2013640.","DOI":"10.31857\/S0320972521060026"},{"key":"ref151","doi-asserted-by":"publisher","unstructured":"Thomas K.J., McCoy M.K., Blackinton J., Beilina A., van der Brug M., Sandebring A., Miller D., Maric D., Cedazo-Minguez A., Cookson M.R. (2011) DJ-1 acts in parallel to the PINK1\/parkin pathway to control mitochondrial function and autophagy. Hum. Mol. Genet., 20(1), 40\u201350.","DOI":"10.1093\/hmg\/ddq430"},{"key":"ref152","doi-asserted-by":"publisher","unstructured":"McCoy M.K., Cookson M.R. (2011) DJ-1 regulation of mitochondrial function and autophagy through oxidative stress. Autophagy, 7(5), 531\u2013532.","DOI":"10.4161\/auto.7.5.14684"},{"key":"ref153","doi-asserted-by":"publisher","unstructured":"Skou L.D., Johansen S.K., Okarmus J., Meyer M. (2024) Pathogenesis of DJ-1\/PARK7-mediated Parkinson\u2019s disease. Cells, 13(4), 296.","DOI":"10.3390\/cells13040296"},{"key":"ref154","doi-asserted-by":"publisher","unstructured":"Imberechts D., Kinnart I.,Wauters F., Terbeek J., Manders L., Wierda K., Eggermont K., Madeiro R.F., Sue C., Verfaillie C., Vandenberghe W. (2022) DJ-1 is an essential downstream mediator in PINK1\/parkin-dependent mitophagy. Brain, 145(12), 4368\u20134384.","DOI":"10.1093\/brain\/awac313"},{"key":"ref155","doi-asserted-by":"publisher","unstructured":"Wang Y., Dai X., Li H., Jiang H., Zhou J., Zhang S., Guo J., Shen L., Yang H., Lin J., Yan H. (2023) The role of mitochondrial dynamics in disease. MedComm, 4(6), e462.","DOI":"10.1002\/mco2.462"},{"key":"ref156","doi-asserted-by":"publisher","unstructured":"Zhang M., Li C., Ren J., Wang H., Yi F., Wu J., Tang Y. (2022) The double-faceted role of leucine-rich repeat kinase 2 in the immunopathogenesis of Parkinson\u2019s disease. Front. Aging Neurosci., 14, 909303.","DOI":"10.3389\/fnagi.2022.909303"},{"key":"ref157","doi-asserted-by":"publisher","unstructured":"Sandoval A., Corzo-L\u00f3pez A., Duran P., Tovar-Soto D., Vargas-Caballero B., Galicia-Salda\u00f1a V., Gonz\u00e1lez-Ram\u00edrez R., Felix R. (2025) The leucine-rich repeat kinase 2 variant LRRK2G2019S up-regulates L-type (CaV1.3) calcium channel via the CaV\u03b23 subunit: possible role in the pathogenesis of Parkinson\u2019s disease. Int. J. Mol. Sci., 26(7), 3229.","DOI":"10.3390\/ijms26073229"},{"key":"ref158","doi-asserted-by":"publisher","unstructured":"Singh A., Zhi L., Zhang H. (2019) LRRK2 and mitochondria: recent advances and current views. Brain Res., 1702, 96\u2013104.","DOI":"10.1016\/j.brainres.2018.06.010"},{"key":"ref159","doi-asserted-by":"publisher","unstructured":"Buck S.A., Sanders L.H. (2025) LRRK2-mediated mitochondrial dysfunction in Parkinson\u2019s disease. Biochem. J., 482(11), 721\u2013739.","DOI":"10.1042\/BCJ20253062"},{"key":"ref160","doi-asserted-by":"publisher","unstructured":"Sosero Y.L., Gan-Or Z. (2023) LRRK2 and Parkinson\u2019s disease: from genetics to targeted therapy. Ann. Clin. Transl. Neurol., 10(6), 850\u2013864.","DOI":"10.1002\/acn3.51776"},{"key":"ref161","doi-asserted-by":"publisher","unstructured":"West A.B., Moore D.J., Biskup S., Bugayenko A., Smith W.W., Ross C.A., Dawson V.L., Dawson T.M. (2005) Parkinson\u2019s disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc. Natl. Acad. Sci. USA, 102(46), 16842\u201316847.","DOI":"10.1073\/pnas.0507360102"},{"key":"ref162","doi-asserted-by":"publisher","unstructured":"Singh F., Ganley I.G. (2021) Parkinson\u2019s disease and mitophagy: an emerging role for LRRK2. Biochem. Soc. Trans., 49(2), 551\u2013562.","DOI":"10.1042\/BST20190236"},{"key":"ref163","doi-asserted-by":"publisher","unstructured":"Shafique A., Brughera M., Lualdi M., Alberio T. (2023) The role of Rab proteins in mitophagy: insights into neurodegenerative diseases. Int. J. Mol. Sci., 24(7), 6268.","DOI":"10.3390\/ijms24076268"},{"key":"ref164","doi-asserted-by":"publisher","unstructured":"Fasiczka R., Naaldijk Y., Brahmia B., Hilfiker S. (2023) Insights into the cellular consequences of LRRK2-mediated Rab protein phosphorylation. Biochem. Soc. Trans., 51(2), 587\u2013595.","DOI":"10.1042\/BST20201145"},{"key":"ref165","doi-asserted-by":"publisher","unstructured":"Mir R., Tonelli F., Lis P., Macartney T., Polinski N.K., Martinez T.N., Chou M.-Y., Howden A.J.M., K\u00f6nig T., Hotzy C., Milenkovic I., Br\u00fccke T., Zimprich A., Sammler E., Alessi D.R. (2018) The Parkinson\u2019s disease VPS35[D620N] mutation enhances LRRK2-mediated Rab protein phosphorylation in mouse and human. Biochem. J., 475(11), 1861\u20131883.","DOI":"10.1042\/BCJ20180248"},{"key":"ref166","doi-asserted-by":"publisher","unstructured":"Pal P., Taylor M., Lam P.Y., Tonelli F., Hecht C.A., Lis P., Nirujogi R.S., Phung T.K., Dickie E.A., Wightman M., Macartney T., Pfeffer S.R., Alessi D.R. (2023) Parkinson\u2019s VPS35[D620N] mutation induces LRRK2 mediated lysosomal association of RILPL1 and TMEM55B. bioRxiv [Preprint], 2023.06.07.544051.","DOI":"10.1101\/2023.06.07.544051"},{"key":"ref167","doi-asserted-by":"publisher","unstructured":"Zhang H., Su Y., Qu Z., Zhang C., Ma S., Li X., Wang Y. (2024) Sonic hedgehog mediates high frequency-dependent deep brain stimulation for the correction of motor deficits in a Parkinson\u2019s disease model. Neurosci. Bull., 40(11), 1732\u20131738.","DOI":"10.1007\/s12264-024-01306-y"},{"key":"ref168","doi-asserted-by":"publisher","unstructured":"Esmaeli M., Dehabadi M.D., Ghanbari A., Yancheshmeh F.S.A. (2025) The role of Sonic hedgehog (SHH) in the formation of motor neurons and neurodegenerative diseases. Discov. Med., 2, 231.","DOI":"10.1007\/s44337-025-00480-w"},{"key":"ref169","doi-asserted-by":"publisher","unstructured":"Gonzalez-Reyes L.E., Verbitsky M., Blesa J., Jackson-Lewis V., Paredes D., Tillack K., Phani S., Kramer E.R., Przedborski S., Kottmann A.H. (2012) Sonic hedgehog maintains cellular and neurochemical homeostasis in the adult nigrostriatal circuit. Neuron, 75(2), 306\u2013319.","DOI":"10.1016\/j.neuron.2012.05.018"},{"key":"ref170","doi-asserted-by":"publisher","unstructured":"Yao P.J., Manor U., Petralia R.S., Brose R.D., Wu R.T.Y., Ott C., Wang Y.-X., Charnoff A., Lippincott-Schwartz J., Mattson M.P. (2017) Sonic hedgehog pathway activation increases mitochondrial abundance and activity in hippocampal neurons. Mol. Biol. Cell, 28(3), 387\u2013395.","DOI":"10.1091\/mbc.e16-07-0553"},{"key":"ref171","doi-asserted-by":"publisher","unstructured":"Dhekne H.S., Yanatori I., Gomez R.C., Tonelli F., Diez F., Sch\u00fcle B., Steger M., Alessi D.R., Pfeffer S.R. (2018) A pathway for Parkinson\u2019s disease LRRK2 kinase to block primary cilia and Sonic hedgehog signaling in the brain. eLife, 7, e40202.","DOI":"10.7554\/eLife.40202"},{"key":"ref172","doi-asserted-by":"publisher","unstructured":"Schmidt S., Luecken M.D., Tr\u00fcmbach D., Hembach S., Niedermeier K.M., Wenck N., Pfl\u00fcgler K., Stautner C., B\u00f6ttcher A., Lickert H., Ramirez-Suastegui C., Ahmad R., Ziller M.J., Fitzgerald J.C., Ruf V., van de Berg W.D.J., Jonker A.J., Gasser T., Winner B., Winkler J., Vogt Weisenhorn D.M., Giesert F., Theis F.J., Wurst W. (2022) Primary cilia and SHH signaling impairments in human and mouse models of Parkinson\u2019s disease. Nat. Commun., 13, 4819.","DOI":"10.1038\/s41467-022-32229-9"},{"key":"ref173","doi-asserted-by":"publisher","unstructured":"Khan S.S., Jaimon E., Lin Y.-E., Nikoloff J., Tonelli F., Alessi D.R., Pfeffer S.R. (2024) Loss of primary cilia and dopaminergic neuroprotection in pathogenic LRRK2-driven and idiopathic Parkinson\u2019s disease. Proc. Natl. Acad. Sci. USA, 121(132), e2402206121.","DOI":"10.1073\/pnas.2402206121"},{"key":"ref174","doi-asserted-by":"publisher","unstructured":"Bae J.-E., Kang G.M., Min S.H., Jo D.S., Jung Y.-K., Kim K., Kim M.-S., Cho D.-H. (2019) Primary cilia mediate mitochondrial stress responses to promote dopamine neuron survival in a Parkinson\u2019s disease model. Cell Death Dis., 10(12), 952.","DOI":"10.1038\/s41419-019-2184-y"},{"key":"ref175","doi-asserted-by":"publisher","unstructured":"Bhardwaj K., Jha A., Roy A., Kumar H. (2024) The crucial role of VPS35 and SHH in Parkinson\u2019s disease: understanding the mechanisms behind the neurodegenerative disorder. Brain Res., 1845, 149204.","DOI":"10.1016\/j.brainres.2024.149204"},{"key":"ref176","doi-asserted-by":"publisher","unstructured":"Bakhit Y., Tesson C., Ibrahim M.O., Eltom K., Eltazi I., Elsayed L.E.O., Lesage S., Seidi O., Corvol J., W\u00fcllner U.; Sudanese Parkinson\u2019s Disease Study Group (2023) PLA2G6-associated late-onset parkinsonism in a Sudanese family. Ann. Clin. Transl. Neurol., 10(6), 983\u2013989.","DOI":"10.1002\/acn3.51781"},{"key":"ref177","doi-asserted-by":"publisher","unstructured":"Ferese R., Scala S., Biagioni F., Giardina E., Zampatti S., Modugno N., Colonnese C., Storto M., Fornai F., Novelli G., Ruggieri S., Gambardella S. (2018) Heterozygous PLA2G6 mutation leads to iron accumulation within basal ganglia and Parkinson\u2019s disease. Front. Neurol., 9, 536.","DOI":"10.3389\/fneur.2018.00536"},{"key":"ref178","doi-asserted-by":"publisher","unstructured":"Musthafa T., Nizami S.K., Mishra A., Hasan G., Gopurappilly R. (2025) Altered mitochondrial bioenergetics and calcium kinetics in young-onset PLA2G6 Parkinson\u2019s disease IPSCS. J. Neurochem., 169, e70059.","DOI":"10.1111\/jnc.70059"},{"key":"ref179","doi-asserted-by":"publisher","unstructured":"Liu J., Tan J., Tang B., Guo J. (2024) Unveiling the role of iPLA2\u03b2 in neurodegeneration: from molecular mechanisms to advanced therapies. Pharmacol. Res., 202, 107114.","DOI":"10.1016\/j.phrs.2024.107114"},{"key":"ref180","doi-asserted-by":"publisher","unstructured":"Kinghorn K.J., Castillo-Quan J.I., Bartolome F., Angelova P.R., Li L., Pope S., Cochem\u00e9 H.M., Khan S., Asghari S., Bhatia K.P., Hardy J., Abramov A.Y., Partridge L. (2015) Loss of PLA2G6 leads to elevated mitochondrial lipid peroxidation and mitochondrial dysfunction. Brain, 138(Pt 7), 1801\u20131816.","DOI":"10.1093\/brain\/awv132"},{"key":"ref181","doi-asserted-by":"publisher","unstructured":"Lin G., Lee P.-T., Chen K., Mao D., Tan K.L., Zuo Z., Lin W.-W., Wang L., Bellen H.J. (2018) Phospholipase PLA2G6, a parkinsonism-associated gene, affects Vps26 and Vps35, retromer function, and ceramide levels, similar to \u03b1-synuclein gain. Cell Metab., 28(4), 605\u2013618.e6.","DOI":"10.1016\/j.cmet.2018.05.019"},{"key":"ref182","doi-asserted-by":"publisher","unstructured":"Sargent D., Moore D.J. (2021) Mechanisms of VPS35- mediated neurodegeneration in Parkinson\u2019s disease. Int. Rev. Mov. Disord., 2, 221\u2013244.","DOI":"10.1016\/bs.irmvd.2021.08.005"}],"container-title":["Biomeditsinskaya Khimiya"],"original-title":[],"language":"ru","deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T17:51:34Z","timestamp":1772646694000},"score":1,"resource":{"primary":{"URL":"http:\/\/pbmc.ibmc.msk.ru\/en\/article-en\/PBMC-2026-72-1-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":182,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026]]},"published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.18097\/pbmcr1648","relation":{},"ISSN":["2310-6905","2310-6972"],"issn-type":[{"value":"2310-6905","type":"electronic"},{"value":"2310-6972","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]}}}